- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
- slider1.jpg
TREATING DEADLY INFLAMMATION
CytoSorb® is a unique blood purification therapy to control deadly inflammation in life-threatening illnesses in the ICU and cardiac surgery. The product is currently approved in the European Union and distributed in 66 countries around the world.
THE POWER OF THE BEAD
Powered by massive surface area, our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
INFORMATION FOR INVESTORS
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
Recent News
- CytoSorbents to Present at the Cowen 41st Annual Health Care Conference
- CytoSorbents 2021: Leadership and Growth in the "New Normal"
- CytoSorbents to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- National Institute for Health and Care Excellence (NICE) Issues Medtech Innovation Briefing on CytoSorb for Reducing Risk of Bleeding During Cardiac Surgery
- CytoSorbents Appoints David D. Cox, PhD, MBA as Vice President - Global Regulatory Affairs
- slider1.jpg
CytoSorbents is a leader in critical care immunotherapy. The company is committed to serving the best interests of our patients and their families, our customers, our employees, and our shareholders.
CytoSorb® is a unique blood purification therapy.The product is currently approved in the European Union and distributed in 58 countries around the world